Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036682 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and EGFR Exon 20 Mutation, sponsored by Cullinan Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 284
- Enrollment target
- 20
- Study locations
NCT04036682 is a Phase 1 study of Non-Small Cell Lung Cancer and EGFR Exon 20 Mutation that is active but no longer recruiting, run by Cullinan Therapeutics. The registered enrollment target is 284 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04036682, a Phase 1 study of Non-Small Cell Lung Cancer and EGFR Exon 20 Mutation, is active but no longer recruiting, sponsored by Cullinan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 284 participants
- Enrollment target
- 20
- Study locations
Study Summary
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
Conditions Studied
Interventions
- DRUG CLN-081
Study Locations (20)
California
- Pacific Cancer Medical Center, Inc - Anaheim
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope at Irvine Lennar - Irvine
- Pacific Shores Medical Group - Long Beach
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- New York University Langone Health - New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Providence Cancer Center - Portland
- Providence Oncology & Hematology Care Clinic-Westside - Portland
Other
- Hong Kong University - Queen Mary Hospital - Hong Kong
- Azienda Ospedaliero Universitaria Careggi - Careggi
Florida
- AdventHealth - Orlando
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Health System - University Hospital - Ann Arbor
New Jersey
- Summit Medical Group PA - Florham Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04036682
The ClinicalTrials.gov registry entry for NCT04036682 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CLN-081 is the first listed.
NCT04036682 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT04036682 about?
NCT04036682 is a clinical study titled "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer". CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
What is the current status of trial NCT04036682?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 284 participants. The study started on 2019-10-31. Estimated completion is 2026-03-31.
What conditions does trial NCT04036682 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, EGFR Exon 20 Mutation.
What interventions are being tested in trial NCT04036682?
The interventions under investigation include: CLN-081 (DRUG).
Who is sponsoring clinical trial NCT04036682?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04036682 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.